Drugs / Pandemic Influenza Vaccine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00755703 | Oct 2008 → Sep 2009 | avian influenza | Altimmune, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00136331 | Oct 2005 → Nov 2006 | influenza | Seqirus | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00320346 | Jul → Sep 2006 | influenza | Seqirus | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pandemic influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00136331 ↗ |
| Modality | Vaccine | “a prototype inactivated, split-virus H5N1 (avian influenza A) vaccine” PMID 18599164 ↗ Jun 2008 |
| Route | Intranasal | “administered via intranasal spray” NCT00755703 ↗ |